Podcasts about wegovy

GLP-1 medications like Ozempic, Wegovy, and Mounjaro have become household names, celebrated as breakthrough treatments for weight loss and obesity. But while headlines showcase dramatic before-and-after photos and promises of rapid transformation, when we step beyond the marketing, a more nuanced reality comes to light.In this candid conversation, Dr. Mark Cucuzzella, a family medicine physician, and Dr. Tro Kalayjian, board-certified in internal and obesity medicine, draw on decades of clinical experience to examine where GLP-1s truly shine, where they fall short, and why the foundation for lasting health can't come from a prescription alone.They make the case for integrating GLP-1s into a comprehensive care plan, one that addresses nutrition, movement, sleep, and stress. Without these pillars, patients face higher risks of side effects, reduced long-term benefits, and the all-too-common rebound weight gain.In this interview, you'll learn:Which patients benefit most from GLP-1 therapy (and which may not)How “medication stewardship” ensures safe, responsible useWhy starting at the lowest effective dose and tapering mattersHow lifestyle-first programs can match or exceed drug results at a fraction of the costDrs. Cucuzzella and Kalayjian remind us that true success lies in restoring metabolic health and building habits that last long after the injection ends. GLP-1 medications can be powerful allies, but they're not a silver bullet. Without a foundation of nutrition, movement, sleep, and stress management, they risk becoming just another short-term fix.Expert Featured:Dr. Mark CucuzzellaWebsite: https://www.drmarksdesk.com/Dr. Tro KalayjianWebsite: https://toward.health/IG: https://www.instagram.com/doctortro/X: https://x.com/DoctorTroResources Mentioned:TOWARD: a metabolic intervention that improves addiction and binge eating symptomshttps://doi.org/10.3389/fpsyt.2025.1612551CMEs Mentioned:Managing Major Mental Illness with Dietary Change: The New Science of Hopehttps://www.mycme.com/courses/managing-major-mental-illness-with-dietary-change-9616Brain Energy: The Metabolic Theory of Mental Illnesshttps://www.mycme.com/courses/brain-energy-the-metabolic-theory-of-mental-illness-9615Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education,...

With the Dow heading into Monday's session in record territory, Carl Quintanilla, David Faber and Mike Santoli explored a big week on tap for the markets -- including Fed Chair Powell's upcoming speech at the Fed symposium in Jackson Hole, Wyoming, as well as retail earnings from Home Depot, Walmart and Target. Novo Nordisk shares get a lift from a double dose of news regarding their blockbuster drugs Wegovy and Ozempic. Also in focus: Ukraine's president and European leaders set to meet with President Trump at the White House, Nvidia rises on analyst calls, why the "force" is with one stock up more than 25% to start the week, Tesla teases a new car in China, a fascinating look at humanoid robots as China showcases advancements in robotics. Squawk on the Street Disclaimer

Novo Nordisk (NVO) jumped higher after the FDA approved the company's Wegovy drug as a liver disease treatment. Dayforce (DAY) rallied more than 25% off reports that Thoma Bravo is looking to acquire the company. Nvidia (NVDA) has more bullish momentum heading into next week's earnings thanks to price target hikes from Morgan Stanley and Cantor Fitzgerald. Sam Vadas explains the biggest market movers starting the trading week.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

This Day in Legal History: Nineteenth Amendment RatifiedOn August 18, 1920, the Nineteenth Amendment to the U.S. Constitution was ratified, guaranteeing women the right to vote and marking a major legal milestone in the struggle for gender equality. The amendment states simply: “The right of citizens of the United States to vote shall not be denied or abridged… on account of sex.” Its passage capped off more than 70 years of organized activism, dating back to the Seneca Falls Convention in 1848. Suffragists like Susan B. Anthony, Elizabeth Cady Stanton, Sojourner Truth, and Alice Paul played pivotal roles in maintaining momentum across generations, despite fierce opposition.The road to ratification was grueling. Congress passed the amendment in 1919, but it still required approval from three-fourths of the states—36 at the time. Tennessee became the critical 36th state, narrowly approving the amendment in a dramatic vote where a 24-year-old legislator, Harry T. Burn, changed his vote after receiving a letter from his mother urging him to support suffrage. That moment tipped the scales and enshrined the right to vote for women nationwide.Before the amendment, several western states had already extended suffrage to women, but many others actively suppressed it. The legal recognition of women's voting rights through constitutional amendment removed any ambiguity and forced all states to comply. The Nineteenth Amendment not only transformed the electorate but also reshaped American democracy by recognizing women as full political participants.The Trump administration is accusing a federal judge in Boston of undermining the authority of the U.S. Supreme Court by continuing to block the administration from firing staff in the Department of Education's Office for Civil Rights. U.S. District Judge Myong Joun had issued an injunction requiring the reinstatement of employees let go in a mass layoff, despite the Supreme Court having recently paused a broader version of that order. The Justice Department has asked the 1st U.S. Circuit Court of Appeals to intervene, arguing that Joun's refusal to lift the narrower injunction contradicts the Supreme Court's ruling and undermines the rule of law.The judge's decision stems from a lawsuit challenging Secretary of Education Linda McMahon's plan to lay off over 1,300 department employees, part of President Trump's broader goal of eliminating the department—something only Congress can authorize. The plaintiffs, including students and advocacy groups, focused specifically on the Office for Civil Rights, which was set to lose half its staff. They argue that lifting the injunction now would effectively reward the administration's ongoing failure to comply with the court's order, as the terminated employees have not yet been reinstated.Judge Joun, appointed by President Biden, criticized the Supreme Court's ruling as "unreasoned" and pointed to the administration's continued noncompliance. The 1st Circuit has asked the plaintiffs to respond promptly to the Justice Department's request, signaling an expedited review.Trump administration claims judge defied Supreme Court to bar Education Department firings | ReutersFederal Reserve Chair Jerome Powell is preparing for what may be his final speech at the annual Jackson Hole conference, facing a complicated economic picture that challenges his data-driven policy approach. In past years, Powell used the conference to pledge aggressive action against inflation and, later, to support the labor market. Now, with inflation still above target and signs of economic slowdown emerging, Powell must decide whether to prioritize price stability or job preservation.The Trump administration and many investors expect interest rate cuts at the Fed's September meeting, but Powell's messaging—how he frames future actions—may matter more than the decision itself. Internally, Fed officials are split: some want to move quickly to protect jobs, while others want to wait for clearer evidence that inflation won't rebound. Powell has previously styled himself after past Fed chairs like Paul Volcker and Alan Greenspan, with Volcker's inflation-fighting resolve and Greenspan's forward-looking leniency both offering competing models.Recent economic data has sent mixed signals. Revised job growth numbers were lower than initially reported, supporting arguments for easing monetary policy, but inflation has edged up again. Trump's tariff policies add further uncertainty, though their economic impact has so far been less severe than feared. With the economy growing slowly and inflation still above the Fed's 2% target, Powell must decide whether to stay the course, cut rates cautiously, or begin a broader shift.Powell has used Jackson Hole to battle inflation and buoy jobs; he's now caught between both | ReutersNovo Nordisk's shares rose by up to 5% after receiving accelerated U.S. approval for its weight-loss drug Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis), a progressive liver disease that affects about 5% of U.S. adults. This marks the first GLP-1 drug approved for MASH and offers a significant, if temporary, advantage over competitor Eli Lilly, which is still in clinical trials for its own MASH-targeting drug, tirzepatide.The news was a welcome reversal for Novo, which recently lost over $70 billion in market value following a profit warning and leadership change. The company, once Europe's most valuable publicly traded firm due to Wegovy's success, has seen its share price drop sharply over the past year amid intensifying competition in the obesity drug market and the rise of compounded copycat drugs.Although Novo now holds a short-term lead in the liver disease market, analysts expect that exclusivity will be brief once Eli Lilly gains approval. Novo has also submitted applications in Europe and Japan, signaling its intention to secure broader global use for Wegovy beyond weight loss.Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment | ReutersNorton Rose's ambitious tech partnership with NMBL Technologies has ended in failure and mutual lawsuits, highlighting how difficult it is for Big Law firms to pivot from selling legal services to selling tech products. The firm's Chicago office, launched in 2022 as an “innovation hub,” aimed to introduce 150 clients to Proxy, a legal workflow tool developed by a new partner, Daniel Farris. But three years later, not a single sale was made. NMBL claims Norton Rose didn't uphold its end of the deal and stifled the rollout, while the firm says clients weren't interested and is seeking damages for the investment.The fallout underscores broader challenges law firms face as they increasingly invest in artificial intelligence and legal tech amid growing demand and rising budgets. Unlike traditional legal work, selling products requires different infrastructure and skills—such as dedicated sales teams—that most law firms lack. Despite producing marketing materials and training resources, NMBL alleges that very few Norton Rose lawyers engaged with the product and that the firm failed to meaningfully promote it.NMBL is seeking $15 million in damages, accusing the firm of using the deal merely to recruit talent, while Norton Rose wants $250,000, calling the product commercially nonviable. The firm also allegedly created a shell subsidiary, LX, to meet contract terms but never properly funded or activated it. This case illustrates the steep learning curve law firms face in transitioning to tech-based business models and the internal resistance that can derail innovation.Firm's Failed Tech Venture Foretells Big Law's AI Sales Struggle This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Stock Market update for August 18, 2025. This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

This week on Two Parents & A Podcast, we sit down with Dr. Morgan Cutlip (PhD in Psychology, relationship expert & author of ‘A Better Share: How Couples Can Tackle the Mental Load for More Fun, Less Resentment, and Great Sex') to talk all things love, parenting, and partnership. From the invisible mental load moms carry (and how it can silently kill your relationship) to why weekly marriage meetings actually work (and how to have them!!!), Dr. Morgan shares her research + real-life advice for building a relationship that thrives after kids. We also get into initiative, resentment, and her #1 secret for a long + happy marriage. If you've ever felt like you're carrying too much, wondering how to bring it up without starting World War III, or just looking for ways to reconnect with your partner—this one's for you :-)  LOVE YOU GUYS!  Timestamps: 00:00:00 Welcome back to Two Parents & A Podcast! 00:00:12 Meet Dr. Morgan Cutlip (PhD in Psychology, author and relationship expert0 00:07:15 Is mom's happiness is the key to your child's happiness? 00:13:32 What is the "mental load" and how is mismanaging it killing your relationship? 00:20:04 How to bring up the mental load conversation without starting a fight 00:25:50 The importance of a weekly relationship meeting  00:33:31 The importance of taking initiative in relationships  00:40:12 The #1 thing you need for a long and happy marriage 00:47:50 LOVE YOU GUYS!  #twoparentsandapod --------------------------------------------------------------- Thank you to our sponsors this week: *BetterHelp: As the largest online therapy provider in the world, BetterHelp can provide access to mental health professionals with a diverse variety of expertise. Our listeners get 10% off their first month at https://www.BetterHelp.com/TWOPARENTS. *Hers: Start your initial free online visit today at https://www.forhers.com/ALEX for your personalized weight loss treatment options. Hers Weight Loss is not available everywhere. Compounded products are not FDA-approved or verified for safety, effectiveness, or quality. Prescription required. Restrictions apply. Wegovy® and Ozempic® are not compounded. Actual price depends on product and plan purchased. *Pendry Newport Beach: Huge thank you to Pendry Newport Beach for hosting us for this episode. Check them out at https://www.instagram.com/pendrynewportbeach & don't miss The Elwood Club at https://www.instagram.com/elwoodclub/?hl=en — a modern members' club built on the traditions of luxury hospitality, located within Pendry Newport Beach. --------------------------------------------------------------- Listen to the pod on YouTube/Spotify/Apple: https://www.youtube.com/@twoparentsandapod https://open.spotify.com/show/7BxuZnHmNzOX9MdnzyU4bD?si=5e715ebaf9014fac https://podcasts.apple.com/us/podcast/two-parents-a-podcast/id1737442386 --------------------------------------------------------------- Follow Two Parents & A Podcast: Instagram | https://www.instagram.com/twoparentsandapod TikTok | https://www.tiktok.com/@twoparentsandapod Follow Alex Bennett: Instagram | https://www.instagram.com/justalexbennett TikTok | https://www.tiktok.com/@justalexbennett Follow Harrison Fugman: Instagram | https://www.instagram.com/harrisonfugman TikTok | https://www.tiktok.com/@harrisonfugman Find our Guest: Instagram | https://www.instagram.com/drmorgancutlip Website | https://drmorgancutlip.com/  Book | https://www.amazon.com/Better-Share-Couples-Tackle-Resentment/dp/1400239672  --------------------------------------------------------------- Powered by: Just Media House – https://www.justmediahouse.com/ --------------------------------------------------------------- Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we're talking about one of the body's most powerful secret weapons for weight loss, blood sugar balance, cravings, and even inflammation. It's not a pill. It's not a fad. It's a now famous hormone your body makes naturally — and its name is GLP-1.If that sounds familiar, it's probably because you've heard about drugs like Ozempic®, Wegovy®, or Mounjaro® — all of which are GLP-1 agonists. These drugs mimic GLP-1 in the body to help people feel full longer, eat less, and lose weight. And yes, they work. But they come with a price — financially and physically — and they're not always a long-term solution.Here's the good news: your body already makes GLP-1 on its own. And with the right diet, lifestyle, and a little knowledge, we can help you naturally enhance your own production — safely and sustainably.So today, , we're going to cover the top 10 natural GLP-1 boosters that you can start using right away — no prescription needed.

Alan interviews Dr. David Clark about a near-fatal heart attack he suffered almost two years ago. Dave describes the dramatic details of the event, from initially mistaking his symptoms for heartburn to his wife heroically rushing him to the emergency room. The episode delves into the importance of being your own health advocate, particularly for dentists and other seemingly healthy individuals who may be at risk without knowing it. Dave emphasizes that a heart attack is one of the few life-threatening events that can be largely preventable if people are armed with the right knowledge. He shares key tests and prevention strategies he learned from his brother, a metabolic cardiologist, and warns against common misconceptions and tests that offer a false sense of security. The conversation highlights the emotional and physical toll the event took on him and his family, ultimately leading him to a renewed perspective on life and his dental career. Key takeaways: Dr. Clark discussed several key prevention ideas and tests that he believes are crucial for all listeners to consider, especially those who appear healthy but may have underlying risks. Be Your Own Health Advocate: Don't blindly trust a single doctor's diagnosis, especially if your symptoms don't align with what they say. Dr. Clark's initial symptoms were dismissed as heartburn by his concierge cardiologist, a diagnosis that could have been fatal. The Troponin Blood Test: If you suspect you've had a cardiac event, no matter how minor, go to the emergency room and specifically ask for a blood test for troponin. Troponin is a protein released when heart muscle is damaged, and it can be detected in your bloodstream for up to 48 hours after an event. A positive result would have led to an immediate diagnosis and intervention for Dr. Clark, preventing the heart attack and damage. Get a CAC (Coronary Artery Calcium) Score: This is a key test for "the healthy guy heart attack." A high CAC score indicates a genetic predisposition to having calcified plaque in your arteries. While a stress test only provides short-term security, a high CAC score is a significant warning sign that a rupture in the plaque could lead to a sudden, fatal heart attack. Be Cautious of Misleading Tests: Dr. Clark and his brother identified several tests that can give a false sense of security or are simply not effective in predicting a heart attack, including the standard stress test and most whole-body scans. Consider a GLP-1 Medication: Based on his brother's recommendation, Dr. Clark started taking a GLP-1 medication (like Ozempic or Wegovy) to reduce inflammation, which is a known contributor to cardiovascular problems. He notes that these medications are not just for weight loss but have significant, positive metabolic effects. Some links from the show: Slide show that Dave's brother, the metabolic cardiologist, put together...PLEASE OPEN THIS LINK! Bioclear Join the Very Dental Facebook group using the password "Gary," "Timmerman," Hornbrook" or "McWethy," "Papa Randy" or "Lipscomb!" The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! -- Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code “VERYDENTAL10” you'll get another 10% off your order! Go save yourself some money and support the show all at the same time! -- The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! -- Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! -- CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!    

This week on Two Parents & A Podcast, we're diving into the benefits of family dinner (we're feeling VALIDATED), baby shower do's and don'ts (including one MAJOR mistake we made), and an in-depth review of the Karen Read trial (yep, you read that right). Before all that… we're in Vancouver!!!! Our FIRST international episode (unless someone digs up that one from the lost files). Harrison rapid-fires his travel recs to help YOU plan your next trip (sorry in advance—he named a chain lol). We also get into how our parents' habits shaped us, the joy of Sunday night dinners, and a new rule that has completely SAVED movie night. Then the fun stuff—our picks for the absolute BEST gifts for new moms (the last one may surprise you). And in Things We DMed: the most attractive (and unattractive) hobbies a man can have, plus… Gen Z is apparently sucking on WHAT?! OK LOVE YOU GUYS!!! 00:00:00 Welcome back to Two Parents & A Podcast! 00:04:02 Rapid-fire Vancouver recommendations for your next trip 00:07:05 Our craziest airport horror stories 00:12:32 How your parents' habits shape who you are today 00:14:40 Sunday night family dinner 00:20:15 Our thoughts on the Karen Read trial 00:27:15 New rule that solved our movie night problem 00:31:46 Baby shower do's and don'ts 00:37:33 The absolute best gifts for new moms 00:47:45 The most attractive (and unattractive) hobbies a man can have 00:52:00 Gen Z's new anxiety trend: PACIFIERS?!  00:52:50 #1 parenting hack: family dinners 00:55:08 THANK YOU FOR LISTENING!!!  #twoparentsandapod --------------------------------------------------------------- Thank you to our sponsors this week: Hers: Start your initial free online visit today at https://www.forhers.com/ALEX for your personalized weight loss treatment options. Hers Weight Loss is not available everywhere. Compounded products are not FDA-approved or verified for safety, effectiveness, or quality. Prescription required. Restrictions apply. Wegovy® and Ozempic® are not compounded. Actual price depends on product and plan purchased. Cozy Earth: Head to https://www.CozyEarth.com and use code TWOPARENTS for up to 40% off! And if you get a Post-Purchase Survey, make sure to let them know you heard about Cozy Earth right here!  Quince: Give your summer closet an upgrade—with Quince. Go to https://www.Quince.com/Alex for free shipping on your order and three hundred and sixty-five-day returns.  --------------------------------------------------------------- Listen to the pod on YouTube/Spotify/Apple: https://www.youtube.com/@twoparentsandapod https://open.spotify.com/show/7BxuZnHmNzOX9MdnzyU4bD?si=5e715ebaf9014fac https://podcasts.apple.com/us/podcast/two-parents-a-podcast/id1737442386 --------------------------------------------------------------- Follow Two Parents & A Podcast: Instagram | https://www.instagram.com/twoparentsandapod TikTok | https://www.tiktok.com/@twoparentsandapod Follow Alex Bennett: Instagram | https://www.instagram.com/justalexbennett TikTok | https://www.tiktok.com/@justalexbennett Follow Harrison Fugman: Instagram | https://www.instagram.com/harrisonfugman TikTok | https://www.tiktok.com/@harrisonfugman --------------------------------------------------------------- Powered by: Just Media House – https://www.justmediahouse.com/ --------------------------------------------------------------- Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Mike discusses the latest GLP-1 craze, which has to do with healthy weight individuals using these medications. ------------------------------------------------Click here to apply for coaching!For some amazing resources and to be a part of a badass community, join our FB group HEREThe personality assessment is now available online! Click here to take the assessment and find out what your personality tells us about the way you should be training and eating.Take the assessment here!To learn more about Neurotyping, visit www.neurotypetraining.comFollow Mike on IG at @coach_mike_millner

It's part 2 of the GLP 1 deep dive! In this episode, we are covering “food noise,” the weird things that people are reporting happening to their bodies on GLP-1s, horrid stuff that's happening in the UK, lawsuits, safety planning for those taking the drugs, and whether taking GLPs goes against fat liberation. TW: for British anti-fatness, side effects, and mental health. Episode show notes: http://www.fiercefatty.com/200 Support me on Ko-Fi and get the Size Diversity Resource Guide: https://kofi.com/fiercefatty/tiers Ragen's 3 bullet points on GLPs: https://www.instagram.com/p/DKa5xdovYxa/?igsh=bHh1Nml0NW82bG83 https://www.cnn.com/2024/05/02/health/wegovy-weight-loss-drug-new-prescriptions Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx The Community Ozempic Stole: As Influencers Lose Weight, Their Followers Feel "Abandoned": https://www.teenvogue.com/story/community-ozempic-stole-influencers-lose-weight Ozempic's Origin Story is Insane: https://youtu.be/9dMpY-ZALXc?si=lb6r-d08fEo9XVKB Dr Rachel Millner: Some thoughts about GLP-1s for intentional weight loss versus fat liberation as a value: https://www.instagram.com/p/DLzrBuuRqfW/?img_index=6&igsh=ODZpMmwyemlhdmxt Another post from Rachel she describes the side effects of GLPs when taken at a higher dose for weight loss and anorexia side effects/complications: https://www.instagram.com/p/DLOUiFKI8TB/ Retatrutide study: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 Ragen's blog: https://weightandhealthcare.substack.com/p/weight-loss-drug-cage-match-part The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx Hannah from Queenbeastsays, The Labour Government wants Britain to be "fat-free" by 2035: https://queenbeastsays.substack.com/p/the-labour-government-wants-britain?utm_source=app-post-stats-page&r=2qfqs8&utm_medium=ios&triedRedirect=true Contraception warning over weight-loss drugs after dozens of pregnancies: UK watchdog has had 40 reports relating to pregnancies in people using drugs such as Ozempic and Mounjaro https://www.theguardian.com/society/2025/jun/05/contraception-warning-over-weight-loss-drugs-after-dozens-of-pregnancies NPP Weight Loss Medications and Safety Planning: https://www.patreon.com/c/nalgonapositivitypride/home 7,000 potential claims already under active investigation Lawsuit Legal News+2Doyle APC Law Firm+2Darrow AI+2.

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comThis week on the podcast, Mikki speaks to Dr Spencer Nadolsky — a board-certified obesity and lipid specialist known for his evidence-based, compassionate approach to helping people lose weight and improve metabolic health. Spencer has dedicated his career to bridging the gap between clinical medicine and the lived realities of people struggling with obesity, cutting through misinformation to focus on what actually works.With the arrival of Wegovy in New Zealand — and the explosion of interest in GLP-1 medications worldwide — their conversation couldn't be more timely. They discuss how these drugs work, how they compare to diet, lifestyle, and older weight loss medications, and why the price tag varies so widely between countries. They also explore the controversies — from “microdosing” to long-term safety, tolerance, and muscle loss — and whether these drugs can genuinely shift someone's metabolic set point or are simply managing symptoms. If you've been wondering whether GLP-1s are game-changing tools or just the latest fad, this episode will help separate the hype from the evidence. Dr. Spencer Nadolsky is an obesity and lipid specialist (DO, ABOM, ABCL) with over a decade of experience. Through practice innovation, digital education, and previous ventures like Sequence and the Docs Who Lift podcast, he's become a trusted, engaging voice in metabolic health.His company, Vineyard, is a virtual obesity medicine clinic delivering personalized, science-backed, and compassionate care. Patients benefit from direct physician access, fast support, individualized plans, and ongoing research—all focused on long-term health, not quick solutions.https://drspencer.com/https://joinvineyard.com/https://podcasts.apple.com/us/podcast/docs-who-lift/id1611961208https://www.instagram.com/drnadolsky/?hl=en  Curranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

GLP-1s like Ozempic, Wegovy, and Mounjaro are everywhere right now—on social media, in ads, and maybe even in your own medicine cabinet. Are they magic? Are they cheating? Maybe even wondered should YOU be on one?In this long-overdue episode, I'm cutting through the confusion with my honest, no-BS take on GLP-1 medications—what they actually do (and what they absolutely don't), the biggest myths no one's talking about, and my real thoughts as a weight loss dietitian and coach. I'm sharing stories from real clients, the muscle loss nobody warned you about, and what you actually need to focus on if you want long-term, sustainable results—GLP-1 or not.We're talking appetite vs. emotions, why so many women regain weight after stopping meds, and the non-negotiable mindset shifts you have to make if you want to keep the weight off—plus, my honest answer to “Should I take it?”If you're on GLP-1s, curious about them, or feeling all kinds of ways about this whole convo, this episode is 100% for you. Let's get real about healing your relationship with food and your body, so you can feel FREE—whether there's a prescription in your bag or not.xoxo,JackieMORE FROM JACKIE: >

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Pharma firms are pouncing on opportunity as patents on world's second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.  

The weight loss injection, Wegovy, arrived in New Zealand - on prescription - with great fanfare only a couple of months ago.

Struggling with weight gain in midlife—even though nothing's changed? Feeling like your metabolism has stalled, your clothes fit differently, and your energy is tanking?You're not broken—and you're not alone.In this episode, Dr. Carolyn Moyers is joined by Dr. Mona Sodhi, internal medicine physician and board-certified expert in obesity medicine, to help you understand what's really going on during the menopause transition and how to take back control of your metabolic health.Together, they break down:Why weight gain in perimenopause isn't your faultWhat GLP-1 medications like Ozempic and Wegovy actually doHow to preserve muscle and protect your metabolism long-termWhy insulin resistance, inflammation, and hormonal shifts matter more than caloriesAnd how personalized, evidence-based care can change everythingWhether you're considering GLP-1s, confused by all the online chatter, or just ready to feel strong and energized again—this episode gives you the science, clarity, and strategy you need to thrive in midlife and beyond.

In this episode of the award winning Steamboat Comedy Podcast, Kyle Ruff and Matt Newland promote their new totally not fake sponsor, Wegovy! Don't diet or exercise, just inject yourself with Wegovy and grow lumps on your neck. Topics also include tech bros throwing dildos, The Menendez Brothers, and Matt's tribute to Kyle while he was away

Margaret and Amy talk with award-winning journalist and author Amy Larocca, whose new book HOW TO BE WELL takes a deeply researched look at the trillion-dollar wellness industry. From supplements to concierge doctors to SoulCycle-as-religion, Larocca exposes how much of modern “self-care” is really about chasing youth, thinness, and unattainable perfection under a new label: wellness. We cover: The real reason “wellness” exploded—and how it's really just rebranded beauty, fitness, and weight loss Why GLP-1 drugs (like Ozempic and Wegovy) are shifting the cultural conversation on body image How women seeking medical care are often underserved, misdiagnosed, or dismissed—and driven toward alternative wellness spaces as a result Why so much wellness messaging is about “getting back to yourself” The role of class, whiteness, and marketing in wellness culture How to protect the next generation—especially our daughters—from internalizing toxic messages about beauty and body image Here's where you can find Amy Larocca: www.amylarocca.com @amylaroccaauthor on IG Buy HOW TO BE WELL: https://bookshop.org/a/12099/9780525655534 We love the sponsors that make this show possible! You can always find all the special deals and codes for all our current sponsors on our website: ⁠⁠⁠⁠⁠⁠⁠https://www.whatfreshhellpodcast.com/p/promo-codes/⁠⁠⁠⁠⁠⁠⁠ mom friends, funny moms, parenting advice, parenting experts, parenting tips, mothers, families, parenting skills, parenting strategies, parenting styles, busy moms, self-help for moms, manage kid's behavior, teenager, tween, child development, family activities, family fun, parent child relationship, decluttering, kid-friendly, midlife women, healthcare, healthcare system, women's health, wellness, wellness industry, healthcare industry, alternative medicine Learn more about your ad choices. Visit podcastchoices.com/adchoices

Wegovy, (often referred to as Ozempic) was approved by the FDA in June 2021. Now that we have lived 4 years of a GLP frenzied hellscape, there must be new data on how well GLP1's work and how many lives they have saved. The numbers must be pretty impressive right? Hint: It's not impressive…not at all. Join me for part one of this deep dive into these (not so) new weight loss drugs where I share exactly how much weight people lose, if it improves their health (or worsens it), and all sorts of other nonsense that has been happening in the ensuing years after the press heralded Wegovy as a “game changer” that will “end” fatness. TW: for mentions of weight, mentions of children taking the drug and other general anti-fat ideas. Episode show notes: http://www.fiercefatty.com/199 Support me on Ko-Fi and get the Size Diversity Resource Guide: https://kofi.com/fiercefatty/tiers Ragen's 3 bullet points on GLPs: https://www.instagram.com/p/DKa5xdovYxa/?igsh=bHh1Nml0NW82bG83 https://www.cnn.com/2024/05/02/health/wegovy-weight-loss-drug-new-prescriptions Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx The Community Ozempic Stole: As Influencers Lose Weight, Their Followers Feel "Abandoned": https://www.teenvogue.com/story/community-ozempic-stole-influencers-lose-weight Ozempic's Origin Story is Insane: https://youtu.be/9dMpY-ZALXc?si=lb6r-d08fEo9XVKB Dr Rachel Millner: Some thoughts about GLP-1s for intentional weight loss versus fat liberation as a value: https://www.instagram.com/p/DLzrBuuRqfW/?img_index=6&igsh=ODZpMmwyemlhdmxt Another post from Rachel she describes the side effects of GLPs when taken at a higher dose for weight loss and anorexia side effects/complications: https://www.instagram.com/p/DLOUiFKI8TB/ Retatrutide study: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 Ragen's blog: https://weightandhealthcare.substack.com/p/weight-loss-drug-cage-match-part The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx Hannah from Queenbeastsays, The Labour Government wants Britain to be "fat-free" by 2035: https://queenbeastsays.substack.com/p/the-labour-government-wants-britain?utm_source=app-post-stats-page&r=2qfqs8&utm_medium=ios&triedRedirect=true Contraception warning over weight-loss drugs after dozens of pregnancies: UK watchdog has had 40 reports relating to pregnancies in people using drugs such as Ozempic and Mounjaro https://www.theguardian.com/society/2025/jun/05/contraception-warning-over-weight-loss-drugs-after-dozens-of-pregnancies NPP Weight Loss Medications and Safety Planning: https://www.patreon.com/c/nalgonapositivitypride/home 7,000 potential claims already under active investigation Lawsuit Legal News+2Doyle APC Law Firm+2Darrow AI+2.

President Trump has announced he will impose a 100% tariff on chips and semiconductors imports, although he's suggested exemptions for companies manufacturing in the U.S. One company that may qualify for that exemption: Apple. During CEO Tim Cook's meeting with the President on Wednesday, Cook committed an additional $100 billion to onshore manufacturing. Author Walter Isaacson discusses Cook's commitment in the context of Steve Jobs' original plans to manufacture Apple products in America. President Trump also has another tech CEO in his sights, calling for the resignation of Intel's Lip-Bu Tan on social media. CNBC's Angelica Peebles reveals the latest obesity pill trial results from Eli Lilly. Orfoglipron's results were similar to Wegovy, and investors are disappointed by the data and the rate of discontinuation among trial participants. Plus, Lyft CEO David Risher explains his company's earnings report, strong on paper but disappointing to some investors.  Megan Cassella - 5:35Angelica Peebles - 13:03Walter Isaacson - 20:47David Risher - 35:21 In this episode:Megan Cassella, @mmcassellaAngelica Peebles, @angelicapeeblesJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinMelissa Lee, @MelissaLeeCNBCKatie Kramer, @Kramer_Katie

En este episodio hablamos sin filtro sobre el uso de inyecciones GLP-1 como Ozempic o Wegovy para bajar de peso. ¿Son una solución o una trampa disfrazada de atajo? Te dire qué es el GLP-1, cómo se activa naturalmente, el impacto emocional y físico que puede dejar el uso sin acompañamiento adecuado y qué no te están diciendo quienes las promueven. Además, comparto 4 testimonios reales de personas que usaron estas inyecciones… y lo que vivieron es alarmante.

After years of struggling with my weight, chronic joint pain, and an up-and-down relationship with food, I made a bold, prayerful, Spirit-led decision to try Wegovy.In this episode, I'm getting real about: Why I chose to start WegovyThe nightmare insurance approval processThe real side effectsLosing 1–2 pounds a week but way more inchesThe food, fitness, and faith shifts that made it work And how this journey became a form of worship, not punishmentThis is not about being skinny. It's about being strong, healthy, and free.Whether you're on your own weight loss journey, curious about Wegovy, or just need encouragement to choose YOU — this one's for you, sis.

Send us a textSo you've lost weight on a GLP-1 medication like Ozempic or Wegovy… but now you're thinking about stopping. What happens next?In this episode, we explore how to maintain your results after coming off GLP-1s. Studies show many people regain weight—but with the right strategies, you can keep the progress going.In this 15-minute episode, you'll learn how to:Rebuild hunger and fullness cues through mindful eatingProtect your metabolism with strength trainingStabilize blood sugar to reduce cravings and prevent fat regainThese aren't quick fixes—they're sustainable habits that will help you transition off medication with confidence and control.Your meds helped you start—now let your habits carry you forward.Listen in, choose one habit to focus on this week, and take your next step toward long-term success.Join us in our private Facebook group. Stop Chasing Wellness: Inner Circle Stop Chasing Wellness is an online wellness coaching company founded by two Holistic Health Coaches, Gina and Kristin. Be sure to check out all of our offerings including our book, Stop Chasing Wellness; Create It, and our growing catalog of Hormone Specific coaching courses. All of our courses and offerings are designed to help you feel and live your best life in a simplified way that works for you. You can find Stop Chasing Wellness on Facebook and Instagram

Plus: Sales of Novo Nordisk's Wegovy soar despite more Americans opting for generic weight-loss drugs. And, the NFL agrees to a tie-up that would see it take a 10% stake and Disney's ESPN. Azhar Sukri hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

(August 06, 2025)About half of U.S. adults say grocery costs cause major stress, poll shows. An old L.A. home is finding new life on an Altadena lot burned by the Eaton fire. Dr. Jim Keany, Chief Medical Officer at Dignity Health St. Mary Medical Center in Long Beach, joins The Bill Handel Show for 'Medical News'! Dr. Keany talks with Bill about doctors urging caution on Benadryl and how tariffs could affect popular weight loss drugs like Ozempic & Wegovy. 

Dr. Jim Keany, Chief Medical Officer at Dignity Health St. Mary Medical Center in Long Beach, joins The Bill Handel Show for 'Medical News'! Dr. Keany talks with Bill about mRNA vaccines and Justin Timberlake having Lyme disease. 

President Trump warns he could escalate pharmaceutical tariffs to as high as 250 per cent with extra levies on chips also on the table. Trump tells our colleagues Stateside, he wants to force producers to bring manufacturing home. In Europe, Novo Nordisk sees a Q2 surge driven by strong sales of its anti-obesity drug Wegovy just a week after a profit warning reduced the drug maker's market cap by $70bn. And in banking news, Commerzbank cites restructuring costs behind its fall in Q2 net profit but the German lender is still upping key targets for the rest of the year. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ozempic, a medication initially approved for managing type two diabetes, continues to be at the forefront of conversations about medical weight loss, especially given the significant news and research developments of the past week. The drug, which contains the active ingredient semaglutide, works by mimicking a hormone called glucagon-like peptide one and has shown effectiveness for weight management by helping to regulate blood sugar and suppress appetite. According to a recent report from Science Daily, three new studies presented at a major neurology meeting this week reveal that Ozempic may also have substantial brain-protective effects, notably reducing deaths from stroke and enhancing patient recovery. In one of these studies, researchers found that stroke patients using Ozempic had markedly lower mortality rates—5 percent for Ozempic users versus over 21 percent for nonusers. The findings have led medical experts to suggest that Ozempic could eventually have a broader role in preventing and mitigating the long-term consequences of stroke, illustrating how the drug's benefits may stretch beyond weight and diabetes management.However, the newfound prominence of Ozempic has also led to more critical scrutiny regarding its safety and long-term effects. A study highlighted by ABC News and KGUN9 in the last week warns that while GLP one agonists like Ozempic help to lower weight and may even protect the heart, they might also contribute to loss of lean muscle mass. Muscle is essential for overall health, physical function, and longevity, so losing it could theoretically raise the risk of heart issues and even early death. Experts are urging patients who use Ozempic or similar drugs to combine them with regular exercise and a protein-rich diet to help counteract muscle loss. Additionally, there is growing legal scrutiny over whether Ozempic's manufacturer gave adequate warnings about the risk of side effects such as gastroparesis, a condition where the stomach slows down digestion too much. Lawsuits are now in progress, focusing on claims that patients were not properly informed about these potential risks. As the popularity and demand for Ozempic increase, some users and doctors are also turning their attention to unregulated GLP one branded supplements, but experts at the Harvard Chan School of Public Health emphasize these supplements do not offer the same clinical benefits and can be potentially unsafe due to a lack of oversight.On the cultural front, Oprah Winfrey's recent candid discussions about her own experience using weight loss medications have made waves this week. In an interview and via social media posts, Winfrey directly addressed the stigma and shame associated with both obesity and the use of medications like Ozempic and Wegovy. She shared her personal struggle with the idea that taking medication is “the easy way out,” but explained that after coming to terms with the scientific evidence supporting these drugs, she is now "absolutely done with the shaming." Oprah emphasized that these medications have given her a sense of control over weight in a way that was never previously possible, and she advocated for shifting public conversations from blame and guilt to compassion and science. However, she also publicly apologized for her role in perpetuating harmful diet culture, acknowledging the need to move away from cycles of restriction and self-judgment. Instead, Winfrey encouraged listeners to approach weight and wellness as multifaceted issues that require medical, psychological, and social understanding.Ozempic's fast-evolving story, with its promise for weight management, potential for new medical benefits, concerns over side effects, and rising influence in wider cultural discussions, signals that the dialogue around weight loss is changing rapidly. The drug is being tested for other health conditions, including cardiovascular disease and even as a potential aid for people with alcohol use disorder or Alzheimer's, pointing to its wide-ranging medical implications. As new data and testimonials like Oprah's reach the public, experts, and patients alike are becoming more aware of both the promise and the complexity of using Ozempic for long-term health.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

In response to the article I wrote in The Times about whether I was daft for not using skinny jabs to lose weight, I thought revisiting my conversation with Johann Hari about his book Magic Pill, which extensively researched the benefits, limitations and risks of GLP-1 Agonist drugs such as Ozempic, Semaglutide, Wegovy and Mounjaro.Johann is thorough and meticulous in his research and this interview, originally broadcast in 2024, was before weight loss drugs became as mainstream and as widely prescribed as they are today.One of the experts Johann interviewed during his years of research, stated that the cultural impact of GLP-1s was as significant as the smart phone. At the time, it seemed like a very bold statement, but in the year since we spoke, I think it's hard to argue that they haven't completely changed the way we talk about weight, weight loss, diets, food and more...I'd love to hear your thoughts on this episode. Email me at office@emmaguns.com or Subscribe to my Substack and join the chat there. Hosted on Acast. See acast.com/privacy for more information.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered why getting obesity medications like Wegovy or Zepbound feels sooo complicated and honestly, kinda impossible sometimes?Between high costs, confusing insurance rules, and endless paperwork, even patients who qualify often struggle to actually start treatment.To help us break it all down, I'm joined by Dr. Nikita Shah, a board-certified obesity medicine physician and founder of WeightSense in Orlando, Florida. She focuses on practical, health-first weight care and also serves on the Medical Society of Central Florida board and the Obesity Pillars Journal editorial board. She's all about helping patients find real-world solutions that actually work.In this episode, we cover everything you need to know about accessing obesity medications, including:Why obesity is a real medical condition, not a personal failure.How cost and insurance create the biggest hurdles.The different coverage rules for medications like Wegovy, Zepbound, and Ozempic.What prior authorization really involves—and how to get through it.Affordable medication options like Qsymia and Contrave.Why most compounded anti-obesity medications aren't the safest choice.If you're ready to finally understand the process, cut through the confusion, and learn the smartest steps to get started, listen to the full episode now!Connect with Dr. Shah:Instagram: nikitashahdoWebsite: Weight SenseBlog Mentioned: Understanding Insurance CoverageConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

When it comes to weight loss, the scale isn't the only thing that changes—your reflection and self-image often transform too. In this episode, I talk about a topic gaining attention in the media and social circles: "Ozempic face" and the emotional and physical effects of rapid weight loss, especially for those using GLP-1 medications like Wegovy, Zepbound, or Ozempic. I share a story about a friend who hesitated to increase her dosage due to concerns about skin changes, which opened the door to a larger discussion on body image during weight loss. I explain that these facial and skin changes—such as sagging, wrinkles, or looking more tired—aren't exclusive to medication use but are common with any significant weight loss, especially as we age.  Furthermore, I walk through ways to manage these concerns, like slowing down weight loss, prioritizing resistance training and protein, staying hydrated, considering aesthetic treatments, and most importantly, shifting focus from appearance to overall health. I emphasize the importance of support, tuning out unsolicited comments, and curating a healthier social media feed.  If you're navigating weight loss and struggling with body image changes like "Ozempic face," listen to this empowering episode for real talk, expert tips, and compassionate support on your journey.   Episode Highlights: What “Ozempic face” really means and why it happens Emotional impact of rapid weight loss and changing appearance How to manage body image concerns during weight loss Practical tips: strength training, hydration, and pacing weight loss Cosmetic treatment options and when to consider them The role of social media in shaping unrealistic expectations Reframing the focus from appearance to overall health and wellness Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode of the Pound of Cure Weight Loss Podcast, Dr. Matthew Weiner and registered dietitian Zoë dive deep into the latest research on GLP-1 medications and their evolving role in weight loss, muscle preservation, and even potential cancer treatment.They break down what the newest studies actually show — including why so many headlines are misleading, and how to interpret scientific research through a more critical lens.You'll also learn why strength training is non-negotiable during GLP-1 therapy or bariatric weight loss, what to know about oral semaglutide vs. injectable versions, and how nutrition plays a key role in maintaining muscle mass while losing weight.Whether you're a patient on Ozempic, Wegovy, Zepbound, or considering medication as part of your obesity treatment, this episode helps you make more informed, science-based decisions.Download our NEW FREE APP now!For Apple: https://apps.apple.com/us/app/a-pound-of-cure/id6741747271For iOS: https://play.google.com/store/apps/details?id=com.digitalbariatrics.poundofcure

This week on the You Are Not Broken podcast, I'm joined by the incredible Dr. Rocio Salas-Whalen, an expert in obesity medicine who breaks down the real science behind GLP-1 medications like Ozempic and Wegovy. Spoiler: they've actually been around since 2005 for diabetes, and only now are we waking up to their potential in treating obesity as the complex disease it is—not a failure of willpower. We talk about how COVID changed the national conversation on obesity, shifting it from “personal choice” to a serious health risk that deserves real medical treatment. We get into how GLP-1s work, why maintaining muscle is critical during weight loss, and the often-ignored psychological shifts that happen when your body changes rapidly. Dr. Salas-Waelin also clears up the noise: Are GLP-1s safe? Are they just for the ultra-rich? Will they be lifelong meds or stepping stones? And what's next in hormone-based obesity treatment? This is a must-listen if you're using—or considering—GLP-1s, working in healthcare, or just want to understand what's really going on behind the headlines. In this episode, we cover: Why GLP-1s aren't actually new—and why that matters How COVID helped the world reframe obesity as a disease The importance of muscle preservation during weight loss How to make sure your protein intake supports your body What happens to your brain when your body changes fast Myths and misconceptions about the safety and use of GLP-1s The future of GLP-1s: personalized care, better formulations, and smarter dosing Why body composition (not just weight) should be part of the conversation This episode is about science, empowerment, and getting real with the tools we have to help people feel better in their bodies—inside and out.

Kara and Scott discuss the advancement of a bill to ban stock trading by lawmakers, President Trump's Joe Rogan problem, and Ghislaine Maxwell agreeing to testify for immunity. Then, President Trump says he will not extend the latest August 1st tariff deadline, and Microsoft and Meta's mega earnings. Plus, Novo Nordisk shares are plummeting after weak growth for Ozempic and Wegovy. Watch this episode on the ⁠⁠Pivot YouTube channel⁠⁠.  Follow us on Instagram and Threads at ⁠⁠@pivotpodcastofficial⁠⁠.  Follow us on Bluesky at ⁠⁠@pivotpod.bsky.social⁠⁠.  Follow us on TikTok at ⁠⁠@pivotpodcast⁠⁠.  Send us your questions by calling us at 855-51-PIVOT, or at ⁠⁠nymag.com/pivot⁠⁠.⁠⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro

Episode 314 Weight-loss drugs Ozempic and Wegovy have been shown to slow down - or even reverse - the ageing process. In a trial of 84 people taking semaglutide, their biological age dropped by 3.1 years on average, with some organs becoming almost 5 years younger. Based on this new research, this finding could make these some of the most impactful anti-ageing drugs on the market. So how are they doing it? Scientists have very nearly created a new lifeform. A synthetic bacterium has been created with 101,000 changes to its genome - clearing up redundant code in its DNA. By freeing up codons in its genetic code, this bacteria could make new kinds of proteins unlike anything that exists naturally - and pave the way for creating virus resistance bacteria. The recent earthquake off the coast of east Russia was the sixth biggest ever recorded. Thankfully the ensuing tsunami has been manageable - unlike previous record-setting quakes. With two large “foreshocks” before the big one, we ask a professor of tectonics about the geology of the region.  Chapters: (00:34) Weight-loss drugs slow down ageing (10:59) Creation of a new synthetic bacterium (21:52) Geology of the Russian earthquake Hosted by Rowan Hooper and Sam Wong, with guests Alexandra Thompson, Michael Le Page, Andrew Steele, Wes Robertson and Lisa Mcneill. To read more about these stories, visit https://www.newscientist.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

GLP-1s like Ozempic and Wegovy are changing how Americans eat, and that has big implications for the dairy industry. In this episode of The Milk Check, host Ted Jacoby III welcomes Paul Ziemnisky, leader of nutrition and industry growth platforms at Dairy Management Inc., and Dr. Chris Cifelli, vice president of nutrition research for the National Dairy Council. Together with the Jacoby team, they unpack what GLP-1 appetite-suppressing drugs mean for dairy demand, and how our industry can win. We cover: How GLP-1s suppress hunger and how dairy's fat + protein combo supports satiety How protein quality matters more than ever, and why dairy still leads the pack How R&D teams are turning classic dairy products into high-protein, low-sugar solutions From gut health to GLP-1 support, this episode dives deep into one of the most important trends shaping dairy today. Join us for The Milk Check episode 81: The Ozempic and GLP-1 shockwave hitting U.S. dairy. Intro with music: Welcome to the Milk Check, a podcast from T.C. Jacoby & Co, where we share market insights and analysis with dairy farmers in mind. Ted Jacoby III: Hello, everybody, and welcome to the Milk Check. Excited to be here today. In addition to our usual suspects, Josh White, Mike Brown, and my brother guest, Jacoby. We've got two special guests today. We have Paul Ziemnisky, leader for nutrition and product science, technology, innovation and industry growth platforms at Dairy Management Inc. Again, we have Dr. Chris Cifelli, vice president of nutrition research for the National Dairy Council. Guys, thank you so much for joining us today. Thank you for taking time out of your busy days to talk about GLP-1s and how it's affecting the dairy industry. We really appreciate it. What are GLP-1s and why are they good for dairy? Dr. Chris Cifelli: I'll start with what they are and then Paul can talk about the consumer point of view. One of the key things whenever we eat food is that feeling of satiety, the feeling of fullness we get during a meal and then the satiation that occurs between meals until we get those body cues again that we're hungry and we want to eat. Unfortunately, in the environment we're in with stress and different factors, our body is a lot off schedule, so we tend to eat a lot more than we may need to on a daily basis. What GLP's are, glucagon like peptide is the official name, it's an appetite suppressant. So, when you eat and especially when you eat fat and protein, the body will release GLP-1 naturally, and that's what starts making you feel full. What these pharmaceuticals are, are ways to keep the levels of GLP-1 up in your body so you feel less hungry throughout the day more naturally. And what that's going to do is you're not going to snack quite as much. You're not going to have those cravings maybe for sweet salty snacks during the day. But with that appetite suppressant, it means that every calorie really then matters when you're eating throughout the day, and that's really where dairy can win. Paul Ziemnisky: To build on that, what it means for dairy is, I think Chris used two magic words, fat and protein. I think fat's been vilified since this early '70s, late '60s, and we've put a lot of effort in investment in proving the value of fat, especially dairy fats. I think you're going to see in the next six months, the acceleration of an acceptance of fat into things like the dietary guidelines and other uses. And the protein side of the equation, we've got the highest quality protein by far. We've got science behind the highest quality proteins and the efficacy of that. And then by the way, consumers, when they purchase anything, taste is number one factor. So, when you look at taste, price, value, health and wellness, we deliver on all those three sweet spots for that consumer. And so, you see things like yogurt on fire because of that,

It's no exaggeration to say that the past decade has revolutionized how we think about and treat obesity. Drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have dominated headlines, enabling significant weight loss at speeds once considered unthinkable. The market for innovative weight loss medications is booming, with pharmaceutical companies investing heavily in hopes of developing the next blockbuster drug.However, amid this race for market dominance, many experts are questioning whether the amount of weight loss alone is the best measure of these drugs' usefulness. How can the next generation of obesity treatments meaningfully improve upon the powerful options already available?Joining The Lancet editors Callam Davidson and Miriam Sabin to discuss this question is Professor Steven Heymsfield from the Pennington Biomedical Research Center. This wide-ranging conversation covers exciting pharmaceutical advances and limitations of these treatments, including the significant disparities in access, and why these breakthroughs may have broader societal implications.Send us your feedback!Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancetCheck out all the podcasts from The Lancet Group:https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancetContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Episode 637: Neal and Toby chat about Boeing's strongest quarter yet as it seems to have successfully turned the tides of its performance. Then, Novo Nordisk, the maker of Ozempic and Wegovy, are losing the lead to other competitors and copycat drugs. Also, the AI surge is also causing a surge in electricity bills for the locals who live around these massive data centers. Plus, Uggs are becoming popular footwear for men as celebrities help boost sales.  Build your Range Rover Sport at RangeRover.com/US/Sport  Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠  Watch Morning Brew Daily Here:⁠ ⁠⁠https://www.youtube.com/@MorningBrewDailyShow⁠ 00:00 - Tsunami warning 2:40 - Boeing bounces back 8:20 - Novo Nordisk loses its edge 11:50 - AI is making electric bills higher 17:50 - Uggs, they're for men too! 21:00 - Sprint Finish!

David Faber and Jim Cramer kicked off a big show with Starbucks CEO Brian Niccol in a "First on CNBC" interview on the company's quarterly results and turnaround plan. Palo Alto Networks CEO Nikesh Arora and CyberArk Software Founder and Executive Chairman Udi Mokady appeared on the program to discuss their companies' $25 billion merger deal.National Economic Council Director Kevin Hassett joined the show with White House reaction to stronger-than-expected Q2 GDP, as well as views on tariffs and the Fed on rate decision day for the central bank. Also in focus: Earnings parade winners and losers, more woes for Wegovy maker Novo Nordisk. Squawk on the Street Disclaimer

Send us a textDr. Meghan Garcia-Webb has been helping CEOs, attorneys, physicians, and consultants look and feel better for years, and she is attuned to the concerns of high achieving individuals, as well as the specific mindset traps that befall even the most organized personality.She is board-certified in Internal Medicine, Lifestyle Medicine, and Obesity Medicine, bringing her patients the latest evidence-based therapies. She is also certified as a life coach through The Life Coach School, the premier choice for physician coaches. Through this unique combination of skills, she has pioneered an innovative hybrid model of customized care, creating lasting results for patients with ease.Dr. Garcia-Webb earned her B.S. at Tufts University, and her M.D. from the University of Vermont Medical School. She completed her residency in internal medicine at the University of Massachusetts. In addition to her clinical work, she produces a weekly YouTube series, Weight Medicine with Dr. Meghan.Dr. Garcia-Webb has been featured in publications such as Time, GQ, Food & Wine, The NY Post, Men's Health, Newsweek, Prevention, and Parade magazine.Find Dr. Meghan Garcia-Webb at-YT- @Weight Medicine with Dr. Meghan MDhttps://weightmedicinemd.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

Plus: JPMorgan Chase nears a deal to take over Apple's credit-card program. And U.S. consumers' economic mood improved this month, but they remained concerned about tariffs and the labor market. Pierre Bienaimé hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber led off the show with a mega-deal to create a transcontinental railroad giant: Union Pacific to acquire Norfolk Southern for $320 a share or $72 billion in cash and stock. Boeing CEO Kelly Ortberg joined the program along with Phil LeBeau after the company slashed losses and posted a Q2 beat. Novo Nordisk shares plunge after the Wegovy maker cuts guidance and appoints a new CEO.  Procter & Gamble reports earnings and names its future CEO. UnitedHealth slides on weak 2025 guidance. Also in focus: A slew of earnings winners and losers, the deadly shooting inside an office tower on Park Avenue in New York City. Squawk on the Street Disclaimer

Thinking about trying Ozempic, Wegovy, or Monjaro? You're not alone. In this episode, Brooke unpacks the pros, cons, and common misconceptions around semaglutide medications for postpartum moms. If you're navigating weight loss, breastfeeding, or just trying to feel like yourself again—this one's a must-listen. What to Listen For: Why semaglutides like Ozempic are not safe during pregnancy or breastfeeding The hormonal impact of semaglutides and why that matters for moms What happens when you stop taking semaglutides without making lifestyle changes Real talk on the side effects—nausea, vomiting, diarrhea, and more Why some moms regret weaning early just to lose weight What blood sugar imbalance means and how to fix it without meds When Brooke might recommend a semaglutide—and when she wouldn't The link between protein, blood sugar, and milk supply How semaglutides may decrease milk supply by affecting prolactin and oxytocin Why slow, sustainable weight loss preserves muscle (and feels better) Semaglutides can seem like a quick fix—but for most postpartum or breastfeeding moms, they're more risk than reward. Brooke encourages moms to first nourish their bodies with real food, movement, and sustainable changes. Medications may have a time and place, but not at the expense of your hormones, energy, or milk supply. --------------------------------------------------------------------------------------------- Breakfast is one of the most important meals of the day, and getting it right can make a huge difference in your energy, mood, and overall health postpartum. If you've been making these common mistakes, don't stress—small changes can have a big impact! Grab my Postpartum Breakfast Guide for easy, balanced meals that will leave you feeling nourished and satisfied. Click the link in the show notes to get yours today! Click Here to Join the Free Workshop: How to Feel Like Yourself Again Postpartum & Reach Your Healthiest Weight without Sacrificing Your Favorite Foods or Milk Supply

Over 40 Muscle Building & Fat Loss Shortcuts with Stan Efferding The impact of ‘island time' on his overall health. (3:16) Shakes are for fakes, eat steaks! (11:55) Supplementation vs whole foods. (16:22) Busting cholesterol myths. (18:18) Energy intake versus energy expenditure with weight loss. (19:48) The components of lifting responsibly as you age. (25:14) Doing the least amount as possible to elicit the most amount of change. (39:08) The benefits of isometrics. (44:21) Eliminating junk volume. (53:19) The value trigger sessions. (58:03) His attitude toward sodium. (1:00:30) Peptide intervention: The good, the bad, and the ugly. (1:12:54) Related Links/Products Mentioned Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code 25MINDPUMP at checkout for 25% off your first month's supply of Seed's DS-01® Daily Synbiotic** July Special: MAPS Split or Anabolic Metabolism Bundle 50% off! ** Code JULY50 at checkout ** Vertical Diet | By Stan Efferding Whole Egg Vs. Egg White Ingestion During 12 weeks of Resistance Training in Trained Young Males: A Randomized Controlled Trial Comparison of once‐weekly and twice‐weekly strength training in older adults Get your free Sample Pack with any “drink mix” purchase! Find your favorite LMNT flavor, or share it with a friend. Try LMNT totally risk-free. If you don't like it, give it away to a salty friend and we'll give you your money back, no questions asked! Visit DrinkLMNT.com/MindPump Stan Efferding - YouTube LEVELEN™ | The Leader in Athlete Sweat Testing | Sweat Test Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Stan “Rhino” Efferding (@stanefferding) Instagram Website Mark Bell (@marksmellybell) Instagram Jay Cutler (@jaycutler) Instagram  Ronnie Coleman (@ronniecoleman8) Instagram Parrillo Performance (@parrilloperformance) Instagram Robb Wolf (@dasrobbwolf) Instagram Ben Carpenter (@bdccarpenter) Instagram Michael Israetel (@drmikeisraetel) Instagram Dr. William Seeds (@williamseedsmd) Instagram  

Karen tackles the surprising link between GLP-1 medication (like Ozempic and Wegovy) and hair loss. As more people turn to these drugs for diabetes and weight management, some are left wondering: is the price of shedding pounds also shedding your hair? Karen explores possible causes behind this side effect, including rapid weight loss, nutritional deficiencies, and hormonal changes, and shares science-backed strategies to help prevent or reduce hair thinning while on these medications.Visit our website itchyandbitchy.com to read blog posts on the many topics we have covered on the show.